ResearcherHacettepe UniversityActive in the last 2 years
Şuayib Yalçın
Matched on ORCID iD 0000-0001-7850-6798; OpenAlex author ID A5076720762, A5104062638. Sources: OpenAlex.
Their work
- Papers
- 12 (first author 1, last author 5)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 24
2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper
Papers 12
- Dynamine 3 as a diagnostic and prognostic biomarker in pancreatic cancer: Implications for early detection and targeted therapy. Last author DOI 10.1080/1354750x.2025.2458104↗
- Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy. Co-author DOI 10.1007/s10147-024-02512-4↗
- The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.01.009↗
- Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.clinre.2023.102091↗
- A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant metastatic pancreatic cancer. Last author DOI 10.1097/cad.0000000000001486↗
- Stereotactic Body Radiotherapy as an Effective Treatment for Pancreatic Cancer. Co-author DOI 10.7759/cureus.38255↗
- A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer. Last author DOI 10.1016/j.critrevonc.2021.103528↗
- The relation between inflammation-based parameters and survival in metastatic pancreatic cancer. Last author DOI 10.4103/jcrt.jcrt_773_19↗
- Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated with gemcitabine+nab-paclitaxel versus gem… Co-author DOI 10.1186/s12885-020-06758-9↗
- Recent advances in the management of pancreatic adenocarcinoma. Last author DOI 10.1080/14737140.2018.1403319↗
- Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pan… Co-author DOI 10.1093/annonc/mdx343↗
- Current and future systemic treatment options in metastatic pancreatic cancer. First author DOI 10.3978/j.issn.2078-6891.2014.030↗
Closest collaborators
The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Deniz Can Güven · 6 shared papers, 2021–2024 · strength 1.14
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant m… DOI 10.1097/cad.0000000000001486↗
- Ömer Dızdar · 5 shared papers, 2021–2024 · strength 0.97
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant m… DOI 10.1097/cad.0000000000001486↗
- Taha Koray Şahin · 4 shared papers, 2021–2024 · strength 0.76
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic ca… DOI 10.1016/j.clinre.2023.102091↗
- Furkan Ceylan · 3 shared papers, 2023–2024 · strength 0.61
- Paper The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic duc… DOI 10.1016/j.pan.2024.01.009↗
- Paper Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line che… DOI 10.1007/s10147-024-02512-4↗
- Paper Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic ca… DOI 10.1016/j.clinre.2023.102091↗
- Hasan Çağrı Yıldırım · 2 shared papers, 2023–2025 · strength 0.57
- Paper Dynamine 3 as a diagnostic and prognostic biomarker in pancreatic cancer: Implications for early detection and targeted… DOI 10.1080/1354750x.2025.2458104↗
- Paper A chance in hopeless cancer: 5-year complete remission after oxaliplatin-based therapy in a patient with BRCA2 mutant m… DOI 10.1097/cad.0000000000001486↗
- Fatih Yay · 1 shared paper, 2025 · strength 0.37
- Saadettin Kılıçkap · 2 shared papers, 2020–2023 · strength 0.25
- Paper Prognostic and predictive value of tumoral DNA damage repair protein expression in patients with resected pancreatic ca… DOI 10.1016/j.clinre.2023.102091↗
- Paper Quality of life study of patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma treated wi… DOI 10.1186/s12885-020-06758-9↗
- Faruk Zorlu · 1 shared paper, 2023 · strength 0.19
- Pervin Hürmüz · 1 shared paper, 2023 · strength 0.19
- Sema Türker · 1 shared paper, 2021 · strength 0.17
- Yusuf Karakaş · 1 shared paper, 2018 · strength 0.14
- Çağatay Arslan · 1 shared paper, 2014 · strength 0.09
- Nuri Faruk Aykan · 1 shared paper, 2020 · strength 0.09
- Abdurrahman Işıkdoğan · 1 shared paper, 2020 · strength 0.09
- Nuriye Özdemir · 1 shared paper, 2020 · strength 0.09
- Metin Özkan · 1 shared paper, 2020 · strength 0.09
- Türkkan Evrensel · 1 shared paper, 2020 · strength 0.09
- Beate S. Schultheis · 1 shared paper, 2017 · strength 0.05
- Markus Dommach · 1 shared paper, 2017 · strength 0.05
- Wolfgang Ekkehard Schmidt · 1 shared paper, 2017 · strength 0.05
- Ralf‐Dieter Hofheinz · 1 shared paper, 2017 · strength 0.05
- Sara De Dosso · 1 shared paper, 2017 · strength 0.05
- Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.05
- Dirk Strumberg · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.